OBJECTIVE: Impulsivity and compulsivity have been implicated as important transdiagnostic dimensional phenotypes with potential relevance to addiction. We aimed to develop a model that conceptualizes these constructs as overlapping dimensional phenotypes and test whether different components of this model explain the co-occurrence of addictive and related behaviors. METHODS: A large sample of adults (N = 487) was recruited through Amazon's Mechanical Turk and completed self-report questionnaires measuring impulsivity, intolerance of uncertainty, obsessive beliefs, and the severity of 6 addictive and related behaviors. Hierarchical clustering was used to organize addictive behaviors into homogenous groups reflecting their co-occurrence. Structural equation modeling was used to evaluate fit of the hypothesized bifactor model of impulsivity and compulsivity and determine the proportion of variance explained in the co-occurrence of addictive and related behaviors by each component of the model. RESULTS: Addictive and related behaviors clustered into 2 distinct groups: Impulse-Control Problems, consisting of harmful alcohol use, pathological gambling, and compulsive buying, and Obsessive-Compulsive-Related Problems, consisting of obsessive-compulsive symptoms, binge eating, and internet addiction. The hypothesized bifactor model of impulsivity and compulsivity provided the best empirical fit, with 3 uncorrelated factors corresponding to a general Disinhibition dimension, and specific Impulsivity and Compulsivity dimensions. These dimensional phenotypes uniquely and additively explained 39.9% and 68.7% of the total variance in Impulse-Control Problems and Obsessive-Compulsive-Related Problems. CONCLUSION: A model of impulsivity and compulsivity that represents these constructs as overlapping dimensional phenotypes has important implications for understanding addictive and related behaviors in terms of shared etiology, comorbidity, and potential transdiagnostic treatments.
OBJECTIVE:Impulsivity and compulsivity have been implicated as important transdiagnostic dimensional phenotypes with potential relevance to addiction. We aimed to develop a model that conceptualizes these constructs as overlapping dimensional phenotypes and test whether different components of this model explain the co-occurrence of addictive and related behaviors. METHODS: A large sample of adults (N = 487) was recruited through Amazon's Mechanical Turk and completed self-report questionnaires measuring impulsivity, intolerance of uncertainty, obsessive beliefs, and the severity of 6 addictive and related behaviors. Hierarchical clustering was used to organize addictive behaviors into homogenous groups reflecting their co-occurrence. Structural equation modeling was used to evaluate fit of the hypothesized bifactor model of impulsivity and compulsivity and determine the proportion of variance explained in the co-occurrence of addictive and related behaviors by each component of the model. RESULTS: Addictive and related behaviors clustered into 2 distinct groups: Impulse-Control Problems, consisting of harmful alcohol use, pathological gambling, and compulsive buying, and Obsessive-Compulsive-Related Problems, consisting of obsessive-compulsive symptoms, binge eating, and internet addiction. The hypothesized bifactor model of impulsivity and compulsivity provided the best empirical fit, with 3 uncorrelated factors corresponding to a general Disinhibition dimension, and specific Impulsivity and Compulsivity dimensions. These dimensional phenotypes uniquely and additively explained 39.9% and 68.7% of the total variance in Impulse-Control Problems and Obsessive-Compulsive-Related Problems. CONCLUSION: A model of impulsivity and compulsivity that represents these constructs as overlapping dimensional phenotypes has important implications for understanding addictive and related behaviors in terms of shared etiology, comorbidity, and potential transdiagnostic treatments.
Authors: Christine Lochner; Lucy Albertella; Martin Kidd; Zelal Kilic; Konstantinos Ioannidis; Jon E Grant; Murat Yücel; Dan J Stein; Samuel R Chamberlain Journal: J Psychiatr Res Date: 2022-06-28 Impact factor: 5.250
Authors: Linden Parkes; Jeggan Tiego; Kevin Aquino; Leah Braganza; Samuel R Chamberlain; Leonardo F Fontenelle; Ben J Harrison; Valentina Lorenzetti; Bryan Paton; Adeel Razi; Alex Fornito; Murat Yücel Journal: Neuroimage Date: 2019-08-02 Impact factor: 6.556
Authors: Roxanne W Hook; Jon E Grant; Konstantinos Ioannidis; Jeggan Tiego; Murat Yücel; Paul Wilkinson; Samuel R Chamberlain Journal: Neurosci Biobehav Rev Date: 2020-10-25 Impact factor: 8.989
Authors: Lucy Albertella; Kristian Rotaru; Erynn Christensen; Amelia Lowe; Mary-Ellen Brierley; Karyn Richardson; Samuel R Chamberlain; Rico S C Lee; Edouard Kayayan; Jon E Grant; Sam Schluter-Hughes; Campbell Ince; Leonardo F Fontenelle; Rebecca Segrave; Murat Yücel Journal: Front Psychiatry Date: 2021-02-23 Impact factor: 4.157
Authors: Jeggan Tiego; Christine Lochner; Konstantinos Ioannidis; Matthias Brand; Dan J Stein; Murat Yücel; Jon E Grant; Samuel R Chamberlain Journal: Psychol Assess Date: 2021-04-08
Authors: Rick A Stephan; Omar M Alhassoon; Kenneth E Allen; Scott C Wollman; Matt Hall; William J Thomas; Julia M Gamboa; Chrissy Kimmel; Mark Stern; Celina Sari; Constance J Dalenberg; Scott F Sorg; Igor Grant Journal: Am J Drug Alcohol Abuse Date: 2016-08-12 Impact factor: 3.829
Authors: Konstantinos Ioannidis; Roxanne Hook; Katie Wickham; Jon E Grant; Samuel R Chamberlain Journal: Neuropsychopharmacology Date: 2019-04-16 Impact factor: 7.853
Authors: Jeggan Tiego; Samuel R Chamberlain; Ben J Harrison; Andrew Dawson; Lucy Albertella; George J Youssef; Leonardo F Fontenelle; Murat Yücel Journal: Sci Rep Date: 2020-09-01 Impact factor: 4.379
Authors: Jon E Grant; Edward T Bullmore; Murat Yücel; Rafa Romero-Garcia; Roxanne W Hook; Jeggan Tiego; Richard A I Bethlehem; Ian M Goodyer; Peter B Jones; Ray Dolan; Samuel R Chamberlain Journal: Neuropsychopharmacology Date: 2020-09-12 Impact factor: 7.853